Derivative exercise or conversion — not an open-market buy.
Traded Jan 7, 2026 · Filed Jan 8, 2026
A big owner of Eli Lilly sold $1.34M of Eli Lilly shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,335,443
Shares × reported transaction price
69 days after results of Oct 30, 2025, 28 days before results of Feb 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1,108.09 on Jan 7, 2026, within 1% of its 52-week high, after a 5% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $1,109.94 (Nov 25, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $1,059.70 on Nov 21, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Mounjaro on Dec 19, 2025, 19 days before this trade.
New use approved (efficacy supplement). Active ingredient: Tirzepatide. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -2.4% | -0.3% | -2.0% |
| 30 days | -1.8% | -0.0% | -1.8% |
| 90 days | -10.2% | -2.0% | -8.2% |
| 180 days | +14.3% | +7.4% | +6.9% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Routine share withholding; mechanical by default.
Derivative exercise or conversion — not an open-market buy.